Basic Information
ID DDInter176
Drug Type small molecule
Molecular Formula C19H36O5
Molecular Weight 344.492
CAS Number 738606-46-7
Description High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease.[L12153] About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed with maximally tolerated statin therapy alone, requiring additional treatment for hypercholesterolemia.[L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous statin treatment.[L12144,L12150]
ATC Classification C10AX15 C10BA10
IUPAC Name 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
InChI HYHMLYSLQUKXKP-UHFFFAOYSA-N
Canonical SMILES CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Useful Links DrugBank ChEBI PubChem Substance ChemSpider Wikipedia ChEMBL ZINC
Interactions with Bempedoic acid
Filter:
Severity level ID Name Mechanism Detail
Interactions with diseases
Filter:
Severity level Disease name Text References
Interactions with foods
Filter:
Severity level Food name Description Management Mechanism References
Interactions with compound preparation
Multi-DRUG trade Multi-DRUG Drug type Warning Note